{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:33:28Z","timestamp":1792740808667,"version":"4.5.0"},"reference-count":45,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To re-evaluate serum samples from our 2007 cohort of patients with single-episode isolated ON (SION), recurrent isolated ON (RION), chronic relapsing inflammatory optic neuropathy (CRION), multiple sclerosis-associated ON (MSON) and neuromyelitis optica (NMO).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We re-screened 103\/114 patients with available serum on live cell-based assays (CBA) for aquaporin-4 (AQP4)-M23-IgG and myelin-oligodendrocyte\nglycoprotein (MOG)-\u03b11-IgG. Further testing included oligoclonal bands, serum levels of glial fibrillar acidic and neurofilament proteins and S100B. We show the impact of updated serology on these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Reanalysis of our original cohort revealed that AQP4-IgG seropositivity increased from 56% to 75% for NMO, 5% to 22% for CRION, 6% to 7% for RION, 0% to 7% for MSON and 5% to 6% for SION. MOG-IgG1 was identified in 25% of RION, 25% of CRION, 10% of SION, 0% of MSON and 0% of NMO. As a result, patients have been reclassified incorporating their autoantibody status. Presenting visual acuity was significantly worse in patients who were AQP4-IgG seropositive (p=0.034), but there was no relationship between antibody seropositivity and either ON relapse rate or visual acuity outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The number of patients with seronegative CRION and RION has decreased due to improved detection of autoantibodies over the past decade. It remains essential that the clinical phenotype guides both antibody testing and clinical management. Careful monitoring of the disease course is key when considering whether to treat with prophylactic immune suppression.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2019-320493","type":"journal-article","created":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T21:16:16Z","timestamp":1558559776000},"page":"1021-1026","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":42,"title":["Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up"],"prefix":"10.1136","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-9749","authenticated-orcid":false,"given":"Axel","family":"Petzold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Khaleeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8141-2394","authenticated-orcid":false,"given":"W Oliver","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B G","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon T","family":"Plant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"2020050722345908000_90.9.1021.1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.146894"},{"key":"2020050722345908000_90.9.1021.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318248dec1"},{"key":"2020050722345908000_90.9.1021.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312601"},{"key":"2020050722345908000_90.9.1021.4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301296"},{"key":"2020050722345908000_90.9.1021.5","doi-asserted-by":"publisher","DOI":"10.1016\/0165-5728(87)90031-2"},{"key":"2020050722345908000_90.9.1021.6","doi-asserted-by":"crossref","unstructured":"Waters P , Woodhall M , O'Connor KC , et al . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015;2:e89.doi:10.1212\/NXI.0000000000000089","DOI":"10.1212\/NXI.0000000000000089"},{"key":"2020050722345908000_90.9.1021.7","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awg045"},{"key":"2020050722345908000_90.9.1021.8","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-63432-0.00020-7"},{"key":"2020050722345908000_90.9.1021.9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"2020050722345908000_90.9.1021.10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"key":"2020050722345908000_90.9.1021.11","doi-asserted-by":"crossref","unstructured":"Lee H-J , Kim B , Waters P , et al . Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. J Neuroinflammation 2018;15.doi:10.1186\/s12974-018-1335-x","DOI":"10.1186\/s12974-018-1335-x"},{"key":"2020050722345908000_90.9.1021.12","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"2020050722345908000_90.9.1021.13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-Associated disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020050722345908000_90.9.1021.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316880"},{"key":"2020050722345908000_90.9.1021.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6957-4"},{"key":"2020050722345908000_90.9.1021.16","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.108"},{"key":"2020050722345908000_90.9.1021.17","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000216139.44259.74"},{"key":"2020050722345908000_90.9.1021.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.06.014"},{"key":"2020050722345908000_90.9.1021.19","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2008.150698"},{"key":"2020050722345908000_90.9.1021.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2009.196550"},{"key":"2020050722345908000_90.9.1021.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0361-9230(03)00091-1"},{"key":"2020050722345908000_90.9.1021.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.01.015"},{"key":"2020050722345908000_90.9.1021.23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"2020050722345908000_90.9.1021.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00189-3"},{"key":"2020050722345908000_90.9.1021.25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jns.2018.01.042","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in patients with optic neuritis and seizures","volume":"387","author":"Gutman","year":"2018","journal-title":"J Neurol Sci"},{"key":"2020050722345908000_90.9.1021.26","doi-asserted-by":"crossref","unstructured":"Ogawa R , Nakashima I , Takahashi T , et al . MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy. Neurol Neuroimmunol Neuroinflamm 2017;4:e322.doi:10.1212\/NXI.0000000000000322","DOI":"10.1212\/NXI.0000000000000322"},{"key":"2020050722345908000_90.9.1021.27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.5692\/clinicalneurol.cn-001224","article-title":"[Cerebral cortical encephalitis with anti-myelin oligodendrocyte glycoprotein (MOG) antibody]","volume":"58","author":"Adachi","year":"2018","journal-title":"Rinsho Shinkeigaku"},{"key":"2020050722345908000_90.9.1021.28","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dmcn.14032","article-title":"Isolated seizures during the first episode of relapsing myelin oligodendrocyte glycoprotein antibody-associated demyelination in children","volume":"61","author":"Ramanathan","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"2020050722345908000_90.9.1021.29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"2020050722345908000_90.9.1021.30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.msard.2018.11.007","article-title":"Acute epileptic seizures in myelin oligodendrocyte glycoprotein encephalomyelitis and neuromyelitis optica spectrum disorder: a comparative cohort study","volume":"27","author":"Yao","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2020050722345908000_90.9.1021.31","doi-asserted-by":"crossref","unstructured":"Jarius S , Paul F , Aktas O , et al . MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 2018;15.doi:10.1186\/s12974-018-1144-2","DOI":"10.1186\/s12974-018-1144-2"},{"key":"2020050722345908000_90.9.1021.32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1474-4422(18)30159-5","article-title":"Applying the 2017 McDonald diagnostic criteria for multiple sclerosis","volume":"17","author":"Petzold","year":"2018","journal-title":"Lancet Neurol"},{"key":"2020050722345908000_90.9.1021.33","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2009.121"},{"key":"2020050722345908000_90.9.1021.34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020050722345908000_90.9.1021.35","doi-asserted-by":"crossref","unstructured":"Ramanathan S , Reddel SW , Henderson A , et al . Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2014;1:e40.doi:10.1212\/NXI.0000000000000040","DOI":"10.1212\/NXI.0000000000000040"},{"key":"2020050722345908000_90.9.1021.36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaneurol.2014.3602","article-title":"Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor \u03b11 subunit in patients with isolated optic neuritis","volume":"72","author":"Martinez-Hernandez","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020050722345908000_90.9.1021.37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/01658107.2015.1072726","article-title":"Clinical profile of anti-myelin oligodendrocyte glycoprotein antibody seropositive cases of optic neuritis","volume":"39","author":"Matsuda","year":"2015","journal-title":"Neuroophthalmology"},{"key":"2020050722345908000_90.9.1021.38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/01658107.2015.1084332","article-title":"Anti-MOG (Myelin Oligodendrocyte Glycoprotein)-Positive Severe Optic Neuritis with Optic Disc Ischaemia and Macular Star","volume":"39","author":"Moura","year":"2015","journal-title":"Neuroophthalmology"},{"key":"2020050722345908000_90.9.1021.39","doi-asserted-by":"crossref","unstructured":"Jarius S , Ruprecht K , Kleiter I , et al . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation 2016;13.doi:10.1186\/s12974-016-0718-0","DOI":"10.1186\/s12974-016-0718-0"},{"key":"2020050722345908000_90.9.1021.40","doi-asserted-by":"crossref","unstructured":"Pache F , Zimmermann H , Mikolajczak J , et al . MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation 2016;13.doi:10.1186\/s12974-016-0720-6","DOI":"10.1186\/s12974-016-0720-6"},{"key":"2020050722345908000_90.9.1021.41","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J Neurol"},{"key":"2020050722345908000_90.9.1021.42","first-page":"1649","article-title":"Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis","volume":"11","author":"Mekhasingharak","year":"2018","journal-title":"Int J Ophthalmol"},{"key":"2020050722345908000_90.9.1021.43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.msard.2018.11.026","article-title":"Unique characteristics of optical coherence tomography (OCT) results and visual acuity testing in myelin oligodendrocyte glycoprotein (MOG) antibody positive pediatric patients","volume":"28","author":"Narayan","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2020050722345908000_90.9.1021.44","doi-asserted-by":"crossref","unstructured":"Liu H , Zhou H , Wang J , et al . Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol 2018.doi:10.1136\/bjophthalmol-2018-313142","DOI":"10.1136\/bjophthalmol-2018-313142"},{"key":"2020050722345908000_90.9.1021.45","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0b013e318283c3ed"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-320493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T04:50:11Z","timestamp":1601095811000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-320493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":45,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,8,14]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/jnnp-2019-320493"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-320493","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]}}}